Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

نویسندگان

  • Guido V Bloemberg
  • Peter M Keller
  • David Stucki
  • Andrej Trauner
  • Sonia Borrell
  • Tsogyal Latshang
  • Mireia Coscolla
  • Thomas Rothe
  • Rico Hömke
  • Claudia Ritter
  • Julia Feldmann
  • Bettina Schulthess
  • Sebastien Gagneux
  • Erik C Böttger
چکیده

Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline use...

متن کامل

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolongation but no arrhythmias occurred. Use of this therapy is justified for patients with limited options.

متن کامل

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region

in Children. 2nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014. http://apps.who.int/ medicinedocs/documents/s21535en/s21535en.pdf 6 Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177–186. 7 Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline a...

متن کامل

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline

The European Respiratory Journal has recently discussed delamanid and bedaquiline and their use in difficult-to-treat cases affected by multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant (XDR-TB) [1–4]. The use of delamanid or bedaquiline is particularly important when four active drugs cannot be identified and included in a regimen, as per World Health Organization (WHO) g...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The New England journal of medicine

دوره 373 25  شماره 

صفحات  -

تاریخ انتشار 2015